Published in J Immunol on May 15, 2004
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses. Clin Exp Immunol (2006) 0.79
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy. Mol Med (2013) 0.78
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest (2006) 3.77
MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol (2010) 2.88
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One (2009) 2.47
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature (2013) 2.19
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis. Sci Transl Med (2012) 2.02
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity (2010) 1.98
Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J Invest Dermatol (2003) 1.93
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes (2010) 1.91
Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Biochem Biophys Res Commun (2011) 1.82
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc (2012) 1.76
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis. Cancer Biol Ther (2008) 1.64
Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges (2008) 1.61
Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther (2004) 1.56
SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS One (2012) 1.55
Role of matrix metalloproteinases in melanoma cell invasion. Biochimie (2005) 1.54
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci U S A (2012) 1.50
The universal character of the tumor-associated antigen survivin. Clin Cancer Res (2007) 1.50
An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer (2011) 1.49
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother (2007) 1.49
SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol (2011) 1.48
Cytotoxic T cells. J Invest Dermatol (2006) 1.47
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res (2009) 1.42
Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of early human pregnancy. Am J Pathol (2003) 1.41
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy (2011) 1.40
The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer (2010) 1.39
Alzheimer's disease and atherosclerosis: passers-by or brothers? Med Hypotheses (2009) 1.39
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol (2005) 1.36
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res (2009) 1.34
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells (2013) 1.33
SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/β-catenin signal network. Cancer Lett (2013) 1.32
Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood (2002) 1.31
Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol (2012) 1.30
Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol (2002) 1.30
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother (2013) 1.27
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res (2013) 1.23
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov (2005) 1.22
Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A (2003) 1.20
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 1.19
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest (2009) 1.19
Characterization of stem cell-like cancer cells in immune-competent mice. Blood (2006) 1.19
Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother (2011) 1.14
Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res (2003) 1.14
Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol (2005) 1.14
IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell (2010) 1.13
An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol (2011) 1.13
Nod1-dependent control of tumor growth. Proc Natl Acad Sci U S A (2006) 1.13
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res (2003) 1.12
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
Pairing of T-cell receptor chains via emulsion PCR. Eur J Immunol (2013) 1.12
A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother (2005) 1.11
High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One (2011) 1.11
CD147 impacts angiogenesis and metastasis formation. Cancer Invest (2009) 1.11
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res (2006) 1.08
A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother (2007) 1.08
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother (2012) 1.08
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci U S A (2003) 1.06
Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol (2011) 1.06
Comment on "Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer". J Immunol (2013) 1.06
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol (2009) 1.06
Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem (2012) 1.06
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res (2013) 1.05
SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells. Carcinogenesis (2013) 1.05
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine (2005) 1.05
Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS One (2013) 1.05
The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol (2010) 1.04
Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res (2007) 1.04
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother (2007) 1.04